Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $149,938 | $132,751 | $93,529 | $194,361 |
| - Cash | $40,622 | $41,249 | $44,920 | $36,056 |
| + Debt | $79,245 | $81,331 | $83,329 | $85,265 |
| Enterprise Value | $188,561 | $172,833 | $131,938 | $243,570 |
| Revenue | $1,741 | $1,907 | $1,629 | $1,860 |
| % Growth | -8.7% | 17.1% | -12.4% | – |
| Gross Profit | $1,741 | $1,907 | $1,629 | $1,860 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$29,023 | -$30,792 | -$37,947 | -$42,198 |
| % Margin | -1,667% | -1,614.7% | -2,329.5% | -2,268.7% |
| Net Income | -$32,250 | -$34,070 | -$37,621 | -$52,153 |
| % Margin | -1,852.4% | -1,786.6% | -2,309.5% | -2,803.9% |
| EPS Diluted | -0.27 | -0.29 | -0.32 | -0.44 |
| % Growth | 6.9% | 9.4% | 27.3% | – |
| Operating Cash Flow | -$24,374 | -$24,587 | -$33,809 | -$27,799 |
| Capital Expenditures | -$2,203 | -$1,362 | -$1,196 | -$98 |
| Free Cash Flow | -$26,577 | -$25,949 | -$35,005 | -$27,897 |